Roche Announces Massive 50 Billion Dollar Investment in the United States

Roche announced plans to invest USD 50 billion in the United States over the next five years. The investment aims to expand the company’s existing presence, which currently includes 13 manufacturing and 15 research and development sites across its Pharmaceutical and Diagnostics Divisions. The initiative is expected to generate over 12,000 jobs, including approximately 6,500 in construction and 1,000 roles at new or expanded facilities.

Expansion spans 8 states, adds 900,000 square feet of capacity, and boosts workforce beyond 25,000 employees

As part of the investment, Roche plans to expand its current workforce of over 25,000 employees across 24 sites in eight U.S. states. The company will enhance and upgrade its manufacturing and distribution infrastructure to support its medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California. Additionally, Roche will build a state-of-the-art gene therapy manufacturing facility in Pennsylvania and a new 900,000 square foot manufacturing center to support its growing pipeline of next-generation weight loss therapies, with the specific location to be announced.

The investment also includes the establishment of a new manufacturing facility for continuous glucose monitoring in Indiana, as well as a new research and development center in Massachusetts focused on artificial intelligence and cardiovascular, renal, and metabolic diseases. Roche will also significantly expand and modernize its existing pharmaceutical and diagnostics R&D sites in Arizona, Indiana, and California.

Thomas Schinecker, Roche Group CEO, stated, “We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

Novartis, Eli Lilly, and Johnson & Johnson unveil major investment plans in the United States

Earlier this month, Swiss pharmaceutical company Novartis announced plans to invest USD 23 billion in the United States. Eli Lilly and Johnson & Johnson have also recently revealed major investments in the country. The announcements from both Roche and Novartis have strengthened Swiss President Karin Keller-Sutter ahead of her scheduled meetings with senior U.S. officials in Washington this week, where she aims to address the potential imposition of a 31% tariff on Swiss exports.

Roche also emphasized that it does not intend to scale back investments in other regions and plans to share more details about its global investment strategy in the coming weeks. Meanwhile, the U.S. government last week launched an investigation into pharmaceutical imports, potentially paving the way for new tariffs. 

The investigation, conducted under Section 232 of the Trade Expansion Act of 1962, is part of a broader effort to apply tariffs on the pharmaceutical and semiconductor sector. The public will have 21 days to submit comments following the publication of notices in the Federal Register. If the investigation leads to tariffs, the administration must finalize them within 270 days of initiation. As of April 5, pharmaceuticals and semiconductors remain exempt from the 10% tariffs applied to imports like steel, aluminum, and automobiles.

In addition to these investigations, the administration is also reviewing imports of copper and lumber, following the imposition of $10 billion in tariffs on steel, aluminum, and the auto industry. President Trump stated he will address tariffs on pharmaceuticals and semiconductors separately and plans to announce the semiconductor tariff rate in the coming week. The investigation will cover not only pharmaceuticals and semiconductors but also pharmaceutical ingredients and related derivative products.

Related posts:

Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech 22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding Trump Moves to Slam Tariffs on Pharma and Semiconductors Over National Security Fears Is Trump Halting Research? Harvard Sues Over Unlawful Funding Freeze and Government Overreach

Author

Denisse Sandoval